Document is current
Any future updates will be listed below
-
Authors
Das, Alvin S. https://orcid.org/0000-0003-2313-977X
Abramovitz Fouks, Avia
Gökçal, Elif
Rotschild, Ofer
Pasi, Marco
Regenhardt, Robert W.
Goldstein, Joshua N.
Viswanathan, Anand
Rosand, Jonathan
Greenberg, Steven M.
Gurol, M. Edip
-
Funding
Funding for this research was provided by:
Andrew David Heitman Foundation (1200-236980)
National Institute of Neurological Disorders and Stroke (NS083711)
National Institute of Neurological Disorders and Stroke (R01NS114526)
National Institute of Neurological Disorders and Stroke (5R01NS096730-04)
National Institute of Neurological Disorders and Stroke (R01NS103924)
National Institute of Neurological Disorders and Stroke (U01NS069673)
National Institute of Neurological Disorders and Stroke (5R01AG026484)
- License Information
-
More Information
Article History
Received: 10 October 2024
Revised: 3 January 2025
Accepted: 6 January 2025
First Online: 24 January 2025
Declarations
:
: MEG received research grants from AVID, Pfizer and Boston Scientific Corporation. JNG received consulting fees from Pfizer, CSL Behring, Takeda, Octapharma, Astrazeneca, Ncontrol, and Cayuga—none relevant to this analysis. The other authors have no relevant financial or non-financial interests to disclose.
: Informed consent was waived given the nature of the study and minimal risk posed to patients.
: The institutional review board of Massachusetts General Hospital approved this study.
: ASD is the guarantor for this study.
